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                                                     ABSTRACT 
      
BACKGROUND: KwaZulu-Natal has a high HIV prevalence and this may play a 
role in the presentation, progression and in the treatment of women with cervical 
cancer. The aim of the study was therefore to determine whether the clinical profile of 
HIV positive women with cervical cancer was different from that of HIV negative 
women. The study took place at the Gynecology –Oncology clinics at Inkosi Albert 
Luthuli Central Hospital (IALCH) and Addington Hospital. 
METHODS:   A retrospective chart review of the characteristics of women with 
cervical cancer were captured on an Excel data sheet from the Medicom database at 
IALCH and from the patient’s files at Addington hospital for the period of 1st January 
2009 to 31st December 2011. 
RESULTS:   Of the 1087 women, 425 (39%) were HIV positive, 561(51.6%) were 
HIV negative and 101 (9.2%) had an unknown HIV status.  HIV positive women 
presented with cervical cancer an average of 14 years earlier than HIV negative 
women (41 years versus 55 years, p<0.001).  Pap smear uptake was low in both 
groups (11.6% HIV negative and 17.3% HIV positive), and HIV positive women were 
significantly more anaemic (46.8% versus 32.7%, p<0.001).  Ninety two percent of 
women were planned for radical radiotherapy and 8 % were scheduled for radical 
surgery. The average waiting period for radical surgery was longer for HIV positive 
women (84 days versus 58 days, p <0.05). For radical and palliative radiotherapy, the 
average waiting period was 85 days and 27 days, respectively. HIV status did not 
influence the waiting time period for radiotherapy.  In women having radical 
hysterectomy, significantly more HIV positive compared to HIV negative women 
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required adjuvant radiotherapy due to positive lymph nodes, 9/15 (60%) versus 5/26 
(19.2%), respectively.   
 
 CONCLUSION: HIV prevalence was 39% among women presenting with cervical 
cancer in Durban.  HIV positive women presented at an earlier age compared to HIV 
negative women, and anemia was more prevalent in HIV positive women. The long 
waiting period for treatment adversely affected the management of HIV positive 




















                                            CHAPTER 1 
            LITERATURE REVIEW OF CERVICAL CANCER 
 
1.1 INCIDENCE 
Cervical cancer is the third commonest malignancy worldwide in females 
(GLOBOCAN, 2008), and accounts for 13% of all their cancers.  In South Africa, it is 
the second most frequent cancer after the breast cancer among women 
(http://www.who.int/hpvcentre).  Globally, cervical cancer is more common in low-
resource than in high-resource settings.  Parkin et al., (2005) reported that in 2002, 
493 000 women were diagnosed with cervical cancer, and that mortality occurred in 
233 000. Recently, the GLOBOCAN 2008 report revealed that more than half a 
million new cases of cervical cancer were diagnosed in 2008, and that 275 000 died of 
the disease, indicating an increase in the burden of disease worldwide, with 85%of 
these occurring in developing countries (GLOBOCAN, 2008). In developed countries, 
the incidence and mortality of cervical cancer has fallen due to strong cervical 
screening programs and improved socioeconomic conditions (Oaknin et al, 2012; 
Walker et al, 1998). 
 
Cervical cancer is a significant public health problem among women in developing 
countries, particularly affecting those who are economically disadvantaged.   It is the 
number one cancer in Bangladesh, India, Tanzania, Swaziland, Zimbabwe, and 
Zambia. Worldwide, after the sub-Saharan African the highest incidence rates are 
mostly in South-Central Asia, South and Central America and The Caribbean.  Age-
Standardized Incidence Rate (ASIR) was highest in Eastern and Western Africa, with 
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34-35 per 100 000, women followed by South Africa with 26 per100 000 
(GLOBOCAN, 2008). 
 
In the developed world, the ASIR is relatively low, with the Australia/New Zealand 
region being 5 per 100 000 and Europe being 8 per 100 000 (GLOBOCAN, 2008). 
Incidence rate has fallen in the United States from 8.3 per 100 000 in 2000 (Ries et al, 
2003) to 5.7 per 100 000 women (GLOBOCAN, 2008). In United Kingdom, the ASIR 
was 8.3 per 100 000 in 2008 (Patnick J, 2011), as  the National Health Services (NHS) 
implemented a screening program in 1998 in the highest risk age group (25-49 years) 
every 3 years, and for those aged 50-64 years, every 5 years.  A recent report showed 
that since the cervical cancer screening programs were implemented, the incidence 
rate has reduced by half over 20 years from 15.9 per 100 000 in 1988 to 8.3 per100 
000 in 2008 (Patnick J, 2011).  In Switzerland, cervical cancer incidence has declined 
due to well-functioning primary and secondary prevention programs (Imesch & Fink, 
2011). 
 
1.2  MORTALITY 
The mortality rate of cervical cancer has followed a similar trend as incidence rate in 
developed countries, as it tends to be diagnosed in the late stages and treatment 
requires infrastructure and resources that are often limited in resource poor settings. 
The mortality rate was lower in the developed world in 2008 (33 000) compared to  
241 000 in developing countries such as 53 000 in Africa, 31 700 in Latin America 
and the Caribbean, and 159 800 in Asia and India (72,825) (GLOBOCAN Report, 
2008).  The age mortality rate was reported the highest in Zambia in 2008  
10 
 
38.6 per 100 000 followed by Tanzania, Zimbabwe and Swaziland, while in South 
Africa, it was 14.5 per100 000.  In developed countries, the age-standardized mortality 
rate is lower such as in England at 2.2 per 100 000 in 2008 (Patnick J, 2011). 
 
The racial/ethnic and socio-economic disproportion also influences the incidence and 
mortality of cervical cancer, a disparity which also persists in developed countries. 
However, the main determinant of this disparity is not well understood.  McCarthy et 
al., (2010) reported that black and Hispanic women had a higher incidence and 
mortality rate than white women in developed countries.  The survival rate of cervical 
cancer also varied in different races as reported by Adams et al., (2009),  with 49% in 
African American (AA) women compared to 66% in European Americans (EA) 
(Adams et al, 2009).   Similarly, low socioeconomic status of women with cervical 
cancer in developed countries also reported the highest mortality in comparison to 
affluent women (McCarthy et al, 2010; Patrick J, 2011).  This study also concluded 
that race/ethnicity was a predictor of late stage presentation, while both race/ethnicity 
and low socioeconomic status were predictors of survival among women with cervical 
cancer. The positive relationship of good survival rate of women with cervical cancer 
and enhanced health care systems is well established in high income countries, 
whereas the health care infrastructure is limited in developing countries resulting in 
poor survival rates (Movva et al, 2008; Redaniel et al, 2009).   
 
1.3  ETIOLOGY 
Human Papilloma Virus (HPV) infection, a sexually transmitted infection, is 
etiologically linked to the development of cervical cancer.  ZurHausen first 
demonstrated a link between HPV and cervical cancer in 1977, and subsequent 
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epidemiological studies supported the evidence (ZurHausen, 2000).  HPV infection is 
easily and silently transmitted, as it does not cause any symptoms. Approximately 
90% of HPV infections resolve within several months of initial infection (Stanely M, 
2010), while persistent high-risk HPV infections are carcinogenic, causing high-grade 
cervical intraepithelial lesions, which eventually progress to cervical cancer if 
untreated.  Persistent HPV infections are associated with integration of the viral 
genome into the host genome and subsequent transformation.  After viral integration, 
two viral gene products, E6 and E7, are expressed, both of which are necessary but not 
sufficient for disease initiation and persistence. Their gene products are known to 
inactivate the major tumor suppressors, p53 and retinoblastoma protein (pRB), 
respectively (Yugawa and Kiyono, 2009). Disruption of these genes causes blocked 
apoptosis and cell–cycle arrest, leading to dysplasia.  
 
Other causative factors include early age of sexual debut, multiple sexual partners, 
Human Immunodeficiency Virus (HIV) infection, smoking, oral contraceptive use, 
alcohol use, high parity, and chronic immunosuppression.  A local study reported that 
lower socio-economic status, alcohol intake, being single or black race appears to be 
the determinant of increased sexual activity and young sexual debut, which often 
results in multiple sexual partners in life (Cooper et al, 2007).  Therefore, these 
multiple factors eventually increase the risk of HPV infection, its persistence and 
progression to cervical cancer and other sexually transmitted diseases.  In young 
women, HPV infection usually occurs after sexual debut and it clears after a period of 
one to two years in the background of a competent immune system. In contrast, HPV 
infection in older women takes long to clear and persistence of HPV infection even in 
immune competent females put them at high risk of developing cervical cancer. 
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HPV prevalence varies with demographic region and HIV status of women, and has 
been reported as 30% in all age groups in a high resource setting (Guido et al, 2013).  
HPV prevalence is doubled (56%) in African countries in HIV infected women (Dols 
et al, 2012).   
 
1.4    LINK BETWEEN HIV, HPV AND CERVICAL CANCER 
The positive link between HPV infection, cervical dysplasia and HIV infection is well 
supported in the literature (Bitz et al, 2013; Langley  et al, 1996; Moscicki et al, 2000;  
Seck et al,1994).  The direct association between HIV and cervical cancer is 
inconsistent compared to HIV and cervical dysplasia (Sasco et al, 2010).  The 
prevalence of HPV infection is high in HIV positive women (53.9%) versus 33% in 
HIV negative women (Jaquet et al, 2012), with Zhonghua et al., (2012) reporting 
almost similar findings of HPV prevalence (44% in HIV positive and 20% in HIV 
negative women).  HIV positive women with a CD4 count of less than 200 mm3, 
regardless of HIV viral load, are at greater risk of acquiring high risk HPV infection 
(Palefsky et al, 1999).  HPV clearance depends on CD4 count,  as women with a CD4 
of less than 200 mm3 and 200-500 mm3 (71% and 32%, respectively) are less likely to 
clear  HPV infection compared to HIV negative women (Rowhani-Rahbar et al, 
2007).  
 
There is a significant relationship between the persistence of HPV infection and the 
degree of immune-suppression. HIV positive women are more at risk of developing 
high grade cervical dysplasia and multiple HPV genotypes infection compared to HIV 
negative women (Peedicayil et al, 2009).  HPV infection persists in immune-
compromised patients, resulting in cervical dysplasia with a shorter latency period, 
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which leads to the development of cervical cancer in younger females (van Bogaert, 
2011). High grade cervical dysplasia in HIV positive women varies with the 
demographics, the degree of immune suppression, such as 6 % in Brazil (Teixeira et 
al, 2012), 30.9 % in South Africa (Swanepoel et al, 2012) and 31 % in Cameroon 
(Mogtomo et al, 2009).  Keller et al., (2012) reported that HIV positive women with 
negative HPV infection and no cervical dysplasia follow the same course as HIV 
negative women.   
 
In South Africa, cancer of the cervix and HIV/AIDS are both endemic, with studies 
reporting an HIV prevalence of 19% in women with cervical cancer (Maiman, 
Fruchter et al. 1993).  This led to the inclusion of cervical cancer as an AIDS defining 
disease by the Centre for Disease Control. HIV prevalence varies in developing and 
developed countries, would also impact on the prevalence of HIV in women with 
cervical cancer.  In Tanzania, the prevalence of HIV was 21% in women with cervical 
cancer (Kahesa et al, 2008), while in South Africa, a similar finding was reported over 
two periods, 21% in 1999 (Moodley 2006) and 21.8% in 2003 (Moodley &Mould, 
2005).  Recent literature showed an increase of HIV prevalence in cervical cancer 
patients of 30% in Tanzania (Matovelo et al, 2012).  In developed settings such as 
USA, the prevalence of HIV in women with cervical cancer was 1% (Calkins et al, 
2006).   Thus the dynamics of cervical dysplasia, HIV infection and cervical cancer is 
significantly different in developing and developed countries. 
 
       1.5  HIV INCIDENCE  
The identification of HIV infection (Barre-Sinoussi et al, 1983) partly explained the 
increased incidence of unusual infections and malignancies reported in1981.  
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According to estimates (UNAIDS /WHO,  2009), approximately 33.4  million people 
are infected with HIV every  year worldwide, and 80% are those from developing 
countries in Sub-Saharan Africa. The disease has been known for three decades, but is 
still a significant public health issue in developing countries, requiring more effective 
strategies and good health infrastructure to control the spread of the disease. 
 
HIV and AIDS are substantial challenges for South Africa, as is indicated by 2008 
data, which shows that approximately 5.2 million people of the total South African 
population were infected with HIV (http://www.hst.org.za). Population based HIV 
prevalence surveys have been undertaken to monitor the disease epidemic, with three 
having been conducted to date in 2002, 2005, and 2008. National HIV prevalence 
estimation of all age groups was 10.6% in 2008, 10.8% in 2005, and 11.4% in 2002. 
In 2008, a higher  prevalence was found in females than in males, the former being 
32.9% in the 25-29 year age group and the latter being 29.1 % in the 30-34 year age 
group (http://www.mrc.ac.za/pressreleases/2009). The highest HIV prevalence was in 
KwaZulu-Natal Province, with 15.8% in 2008. 
 
In South Africa, an antenatal survey also highlighted that HIV infection is increasing 
(0.7% in 1990, 17% in 1997, and 29.5% in 2004) (National HIV and SYPHILIS 
Prevalence Survey Report, 2005).  A 2010 Antenatal Survey Report, suggests that the 
prevalence has stabilized over the last few years at 30.2%.  The highest HIV 
prevalence was in KwaZulu-Natal, which increased from 38.7% in 2008 to 39.5% in 
2009 and then decreased to 37.4% in 2011 (Antenatal HIV and Syphilis Survey 2011 
Report).  This decline of 2.1% could be due to multiple factors e.g. improved 
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counseling or education of the patients by the medical personnel and media/school 
education or people are now more conscious and therefore careful. 
In Europe, the number of HIV infections is also rapidly increasing, which could be 
due to immigrants and change in lifestyle. In 2008, 1.5 million people were living with 
HIV, compared to 900 000 in 2001.  In Latin America, at the end of 2008, 
approximately 2 million people were living with HIV.  During that year, an estimated 
77 000 people died of AIDS, and approximately 170 000 were newly infected 
(UNAIDS/HIV, 2008). 
 
1.6  PRESENTATION  
Cervical cancer is traditionally a disease of women in the fifth decade of their life, 
with  the  peak  age between  45 and 55 and a mean age of  51  years, but  because of  
HIV  infections,  this  mean  age  will  differ.  Cervical cancer in HIV positive women 
presents 10 years earlier than in HIV negative women, with the mean age of 44 years 
versus 53 years respectively (Lomalisa et al, 2000), this being similar to  finding 
reported by another local study (41 years versus 54 years) (Moodley & Mould, 2005). 
HIV infection did not change the magnitude of the disease at presentation, but an HIV 
positive women with a CD4 count of less than 200mm3 had a more advanced cancer at 
presentation compared to an HIV negative women (77% and 55.8%, respectively) 
(Lomalisa et al, 2000).  Trends in cervical cancer have changed worldwide, with the 
prevalence of cervical cancer increasing in younger women < 35 years for the past 30 
years (2.8% to 15.7%) (Cai et al, 2010). This could be due to earlier sexual debut, 
multiple partners, and acquiring sexually transmitted disease resulting in earlier 




1.7  CLINICAL DIAGNOSES AND INVESTIGATIONS 
The diagnosis of cervical cancer is made by histology of cervical lesions, and more 
than 90% of patients will present with these symptoms.  The most common presenting 
complaints are abnormal vaginal bleeding, history of post coital bleeding, profuse 
purulent or sanguineous offensive discharge.  It can manifest in both premenopausal 
and postmenopausal age groups.  Approximately 10% of women with cervical cancer 
are diagnosed by cervical cancer screening, this group usually being asymptomatic.  
Less common complaints include pelvic pain, pelvic pressure, inguinal or sciatic pain, 
urinary frequency, hematuria, and oliguria, suggesting advanced disease.  In case of 
advanced disease, the patient may have urinary and fecal incontinence secondary to 
vesico-vaginal and recto-vaginal fistula (Biewenga et al, 2010). 
 
Other constitutional symptoms such as pallor, weight loss, and weakness may occur, 
while anaemia may occur in early stages due to abnormal heavy vaginal bleeding.  A 
physical examination may reveal grossly normal appearing cervix with micro invasive 
disease.  As the disease progresses, physical signs appear which include a large, 
irregular and firm cervix, with the involvement of parametrium, thickening of utero-
sacral and cardinal ligaments. Growth pattern can be endophytic, a barrel shaped 
cervix or exophytic, where the lesions are friable, cauliflower-like, and bleeds to 
touch.  Any gross obvious lesion should have a directed punch biopsy or small 
excisional biopsy. Colposcopy is offered to the asymptomatic women who have been 
found to have premalignant lesions on Pap smear. In the absence of an obvious lesion 
on colposcopy, endo-cervical curettage, endometrial biopsy and cervical cone biopsy 




Women with histologically confirmed cervical cancer need further investigation to 
stage the disease and to assist in optimizing the clinical condition of the patient where 
indicated before embarking on treatment. This includes biochemical (full blood count, 
renal and liver function test and glomerular filtration rate) and radiological (chest x-
ray and ultrasound of abdomen) investigation to stage the disease.  In addition, 
syphilis serology, HIV testing and CD4 count if indicated, are also essential.  Proper 
staging of cervical cancer is crucial, as it influences the management of the patient and 
survival outcome (Allen and Narayan, 2005).  
 
1.8 PREVENTION 
Cervical cancer is a preventable disease by initiating primary and secondary 
prevention programs, with the primary prevention program being HPV vaccination, 
which has been implemented in some developed countries. Cervical cancer screening 
programs (secondary prevention) have contributed to the considerable decline in the 
prevalence of the disease in developed countries (Patnick J, 2011; Denny L, 2012).  In 
South Africa, there is a national cervical cancer screening policy that offers all 
asymptomatic women three free pap smears in a lifetime beginning at the age of 30 
years, 10 years apart.  However, this has not been successfully implemented.  The 
ultimate goal is to screen at least 70% of women, nationally, within the target age 
group within 10 years of initiating the program 
(http://www.kznhealth.gov.za/cervicalcancer.pdf). 
 
It has been shown that developing countries have poor Pap smear uptake (19%) 
compared to developed countries (63%) (Gakidou et al, 2008).  Cervical cancer 
screening uptake is approximately 80% in developed countries, such as Austria, 
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compared to 13% to 18% in South Africa (Batra et al, 2010; Hoque et al, 2008).   
There was a poor utilization of cervical cancer screening program in high socio-
economic and high educational background women (87%) in the urban area of 
Durban. This reflects a poor knowledge or lack of importance of screening 
information provided by the health care system (Wellensiek et al, 2002).  Lourenço et 
al., (2012) reported poor knowledge of Pap smear among the women.   South Africa 
currently recommends annual Pap smear for the HIV positive women at the wellness 
clinic since the ARV roll out program, but unfortunately, coverage is still poor, even 
in these targeted groups. Cervical cancer screening coverage is poor in HIV positive 
women in Eastern Europe (30%)  (Bailey et al, 2012).  Similarly, local studies also 
reported low Pap smear coverage (13%) in HIV positive women (Batra et al, 2010). 
 
1.9 STAGING 
Cervical cancer survival outcome depends on the stage of the disease, histology type, 
tumor grading, age of women and their immune status.  Staging of cervical cancer 
according to the extent of the growth was first published in 1929 by the Cancer 
Commission of Health Organization (http://www.figo.org/publications/annual).  FIGO 
(International Federation of Gynecology and Obstetrics) was founded in 1957 and 
adopted the staging system in 1958, which is largely based upon physical 
examination.  A good pelvic examination is essential, and should be performed by an 
experienced gynecologist or Gynae-Oncologist and, under certain circumstances, may 
be performed under anesthesia. 
 
Cervical cancer spreads locally by extension to the corpus, parametrium and vagina, 
and the cervix and entire vagina should therefore both be inspected and palpated to 
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identify overt tumors and sub-epithelial vaginal extension.  Tumor size and 
parametrial involvement are best assessed by recto-vaginal examination.  Cystoscopy, 
intravenous pyelography and sigmoidoscopy may be used to assess adjacent areas in 
case of uncertainty and suspicious lesions should confirmed by biopsy (Allen and 
Narayan, 2005). 
 
Proper staging of cervical cancer is essential, as it influences the management of the 
patient and their survival. Unfortunately, clinical staging is subjective and only gives 
an approximate estimate of extent. This can result in over-staging and/or under-
staging of the disease, which are common when compared to the surgical staging 
(Lagasse et al, 1980). Non-surgical staging is still a gold standard for advanced 
cervical cancer treatment planning.  
 
Imaging evaluation may be of additional benefit to clinical examination in certain 
cases where resources allow. Compared to CT scan/MRI, PET-fdg imaging technique 
is more accurate in detecting metastatic lymphadenopathy, having the potential to 
significantly change the management and survival. Sensitivities remain suboptimal 
and possibly secondary to technique dependent (www.sign.ac.uk/cervical cancer 
guidelines).  Surgery may be avoided in patients with PET-FDG –avid primary 
tumors.  However, there is insufficient evidence of its routine use in operable stage of 
cervical cancer. The long-term survival of patients who had surgical staging-guided 
radiation therapy is no different to imaging guided radiotherapy in advanced cervical 
cancer, (overall survival 68% versus 62%, respectively), and disease free survival is 




Cervical cancer stage presentation showed geographical variation, depends upon the 
healthcare system, early diagnosis (Kinney et al, 2003) good socioeconomic 
conditions and immune status of women (Akinyemiju TF, 2012; Lomalisa et al, 2000). 
Women with advanced stage disease at presentation in South Africa are usually of 
rural background, African ethnicity, old age and lack of health insurance coverage 
(Ibrahim et al, 2011).  HIV infected women with high CD4 count presented at an early 
stage compared to low CD4 count (Lomalisa et al, 2000). 
1.10  HISTOLOGY 
Different pathological types of cervical cancer occurs, but data based on SEER (data 
of 2000-2004 assessed in 2007) showed that  squamous cell carcinomas account for 
approximately 70% of cervical cancers, adeno-carcinomas 25 %, and adeno-squamous 
carcinomas 3-5 %.  Adeno-squamous tumors exhibit both glandular and squamous 
differentiation, and are associated with a poorer outcome than squamous cell 
carcinomas or adenocarcinomas. Other tumors, such as neuro-endocrine or small cell 
carcinomas, can originate in the cervix but are infrequent. Rhabdo-myosarcoma of the 
cervix is rare, usually occurring in adolescents and young women, while primary 
cervical cancer lymphoma (Binesh et al, 2012) and cervical sarcoma are also rare 
(http://screening.iarc.fr/atlasclassifwho.php). 
 
The histological pattern of cervical cancer has also changed over the last three decades 
and exhibit geographic variations.  Squamous cell carcinoma is declining compared to 
adenocarcinoma, and the etiology remains elusive (Smith et al 2000; Wang et al, 
2004).  Wang et al., (2004) reported the linear increase in adenocarcinoma in black 
women, while recent literature reported a higher incidence of adenocarcinoma in 
white women compared to black women based on 35 year population analysis (USA) 
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(Adegoke et al, 2012). This implies the need of better cervical screening program 
including HPV typing.  In sub-Saharan Africa, squamous cell carcinoma is more 
common and presents in an advanced stage (Adewuyi et al, 2008; Chirenje et al, 2000; 
Ndlovu N, &Kambarami R, 2003). HIV infection found to be six times more likely to 
have poor tumor differentiation (Matovelo et al, 2012). 
1.11  TREATMENT 
Cervical cancer treatment modality depends on the stage of the disease, the clinical 
condition and the desire for fertility, with accurate clinical staging being crucial before 
deciding on the choice of treatment to be offered.  Radical hysterectomy with or 
without neo-adjuvant therapy is the preferred treatment of choice for early stage 
disease (stage Ia1-IIa1).  Stage I B2 and above are the bulky tumors and usually 
require neo-adjuvant therapy. The outcome following surgery depends on various 
prognostic factors including tumor size, depth of stromal invasion, nodal involvement 
and presence or absence of lymph-vascular involvement. The presence of these factors 
determines the need for adjuvant chemo-radiation therapy, which may reduce the risk 
of recurrence and improves the survival of women (Memarzadeh et al, 2003; 
Mouková et al, 2013). 
Concurrent chemo-radiation (CCRT) or radical radiotherapy are option of treatment 
for women with locally advanced stage cervical cancer (stage IIa and above). CCRT is 
a platinum based therapy and is better than radiation alone, and significantly improve 
the survival benefit (Green et al, 2005).  Distant metastatic disease may also be treated 
by systemic chemotherapy, while advanced stage disease requires palliative care and 
/or palliative radiotherapy.   
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In developed countries, the well-established health care system offers earlier diagnosis 
of cervical cancer and earlier treatment, which influences the survival outcome.  
Generally, 4-5 weeks are an accepted waiting time for initiating radiotherapy or 
chemo radiation after the treatment plan (http://www.cancerresearchuk.org).  The 
recommended initiation of treatment within 6-8 weeks is acceptable by most 
authorities (González San Segundo et al, 2005).   
Wyatt et al., (2003) reported that a delay of 1-2 months would influence the tumor 
progression and survival outcome in the case of fast growing tumors.  A continuum 
increase in waiting time has been observed in the initiation of radical radiotherapy 
treatment as compared to palliative treatment, even in developed countries (Coles et 
al, 2003).  Similarly, waiting time for surgery of cancer has also increased over the 
years (Bardell et al, 2006).  Various factors contribute to this delay, including patient 
related and health care system factors, which result in delayed diagnosis and referral, 
long waiting lists for treatment, shortage of resources and missed appointments due to 
poor socio-economic status. Patient related factors are usually old age and delay in 
seeking help for cervical cancer, and are more prevalent in developing than developed 
countries (Kaku et al, 2008; Ma et al, 2012). 
 
1.12  OUTCOME 
Survival outcome of women with cervical cancer depends on several prognostic 
factors, these being the stage of the disease, nodal status, tumor volume, depth of 
cervical stromal invasion, lympho-vascular space invasion (LVSI), and histology type 
and grade.  Furthermore, HIV status of the women, CD4 count, tolerance and 
completion of radiotherapy also influence the outcome (Simonds et al, 2012). 
23 
 
In HIV positive women with cervical cancer, radiotherapy toxicity contributes to 
delayed or incomplete treatment.  Shrivastava et al., (2005) reported that more than 
50% of women who presented with advanced stage cancer showed poor compliance 
(24%) to radiotherapy. In a local study, Simonds et al., (2012) also showed that 53% 
of HIV positive women with advanced stage disease were less compliant with 
radiotherapy treatment, resulting in poor survival.   
The 5-year survival of cervical cancer after radical hysterectomy and lymph-node 
dissection in early staged disease (FIGO Stage IB or IIA) was 88% to 96% in those 
who had negative pelvic lymph nodes, compared to 64% to 74% in those with similar 
stage disease and pelvic nodal metastasis. For the advanced stage disease (Stage II B 
to Stage IV), the 5-year survival rate is 65% to 9.3%, respectively (Quinn et al, 2006).   
However, overall survival of the women with cervical cancer depends on the other co-
morbidities such as HIV infection with low CD4 count, tolerance to antiretroviral 
therapy, response to chemo-radiation and occurrence of side effects, and patient’s 
performance status (Simonds et al, 2012; Spoozak et al, 2013). 
 
    1.3   PURPOSE OF STUDY 
The purpose of the study was to determine whether the clinical profile of HIV positive 
women with cervical cancer was different from that of HIV negative women. New 
information gathered from this study may assist in modifying existing practices of 







                                                  CHAPTER 2 
                                   AIM AND METHODOLOGY 
 
2.1 Aim of the study  
To determine the clinical profile of HIV negative and HIV positive women presenting 
with cervical cancer. 
 
2.2 Methods: 
This is a retrospective descriptive study.  Inkosi Albert Luthuli Central Hospital 
(IALCH) and Addington Hospital are the main sites of the study which serves tertiary 
level oncology services in KwaZulu-Natal (KZN).   Women who presented with 
histologically confirmed cervical cancer to the Gynecology Oncology clinics and who 
were admitted to the oncology ward at IALCH and Addignton hospitals were included 
in the study.  
 
The study period was from 1st January 2009 to 31st December 2011.  Information 
regarding  demographic and clinical characteristics, HIV infection and HAART, 
staging and treatment of women with cervical cancer was captured on an Excel data 
sheet from the Medicom database at IALCH and from the patient’s files at Addington 
hospital and imported to SPSS version 21 for the statistical analysis.. 
 
 The analysis of patients’ demographics and outcome variables were summarized 
using descriptive summary measures: expressed as mean (standard deviation) or 
median (minimum-maximum) for continuous variables and as percentages for 
categorical variables.  All statistical tests were performed using paired student t-test at 
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the 0.05 level of significance. Anova test was performed for the comparative analysis 
of treatment in HIV negative and HIV positive women with cervical cancer. 
        
Ethical approval was obtained from the University of KwaZulu-Natal before the study 

























                                            CHAPTER 3 
                                               
                                              RESULTS 
 
3.1 Introduction 
This chapter presents the study findings with respect to the number of women who 
were recruited to study both HIV negative and positive women with cervical cancer 
(figure 1).  


















n=59 (5.4%) excluded due to 
unknown HIV  
n=708 
Comparative analysis  
HIV positive 










*n=71(6.5%)   
For supportive care and demised 
*n=249 (22.9%) Did not return: 
Poor health status and demised 
n=1087  
HIV negative n=561(51.6%) 
HIV positive   n=425 (39.0%) 
HIV unknown n=101(9.2%) 
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3.2 Demographics characteristics 
     The demographic analysis of 708 women with cervical cancer who received treatment 
and followed up is displayed in table 1 and age presentation in figure 2. 
 
      Table 1:  Demographic characteristics of 708 women with cervical cancer 
  HIV negative 
 n=403 




Age  (years)      (mean ± SD)   








Parity                median( range) 5 (0-14) 3 (0-11) <0.001 
Weight (kg)       (mean ± SD) 74.66±17.43 72.14±18.49 0.63 
BMI* (kg/m2)    (mean ± SD) 29.91±7.11 28.45±6.90 0.38 
        
Race  n (%)      <0.001 
      African 342 (84.8) 300  (98.3)  
      Indian 50   (12.4) 2      (0.65)  
      White 7     (1.7) 1      (0.32)  
      Colored 4     (0.99) 2      (0.65)  
        
Previous Pap Smear n (%) 47  (11.6) 53 (17.3) <0.001 
 
Co-morbidities n (%) 
      
       Hypertension 165 (40.9) 42  (13.7) <0.001 
       Diabetes  49   (12.1) 9    (2.9) <0.001 
      Tuberculosis  13   (3.2) 36   (11.8) <0.001 





Figure 2:  Age of presentation of HIV negative and HIV positive women 
 
 
 3.3 Clinical characteristics  
The clinical characteristics of women with cervical cancer regarding stage 
presentation, histology and investigations among the two groups are displayed in 
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Age groups ( years)
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Table 2: Staging and Histology of cervical cancer 







Stage I n (%) 
       Ia1 
       Ia2 
       Ib1 
       Ib2 
 
Stage II n (%) 
       IIa1 
       IIa2 
       IIb 
 
Stage III n (%) 
         IIIa 
         IIIb 
 


















29  (7.1) 
16 
13 


































Histology n (%) 
Squamous cell  carcinoma 
Adeno squamous carcinoma 
Adenocarcinoma carcinoma 
Undifferentiated carcinoma 
Small cell carcinoma 
     Others 
 
332 (82.3)       
18     (4.4)         
24     (5.9)           
11     (2.7)          
7       (1.7)                   
10     (2.4) 
                     
262 (85.9)     
14     (4.5)                
13     (4.2)      
8       (2.6)     
5       (1.6)                
1       (0.3) 
NS 

















3.4 Treatment Planned and Received   
Table 4 presents the cervical cancer treatment was scheduled at the first visit to 
gynecology oncology clinic.  Ninety two percent of the women were scheduled for 
non-surgical treatment and 8% for surgical treatment.  Between 17 to 20 % of women 










Hemoglobin n (%)   
> 10gm/dl    
                8-10 gm/dl   
<8gm/dl     
 
Anemia < 10 gm/dl n(%)           
 
Renal failuren (%) 
              GFR < 60  
              Requiring dialysis 
 
Metastases n (%) 
 
              Chest 
  Liver 
              Bladder  
              Rectum   
 
Performance score (Zubrod) n (%) 
Asymptomatic(score0)                                  
Symptomatic but completely ambulatory (Score1)  
Symptomatic, <50% in bed during the day (score 2) 
Symptomatic, >50% in bed, but not bedbound (score3) 
Bedbound (score 4) 
 
271  (67.2) 
92    (22.8) 





87    (21.5) 
16    (3.9) 
 
29     (7.1) 
 
11    (2.7) 
10    ( 2.4) 
7      (1.7) 





64    (15.8) 
24    (5.9) 
1     (0.24) 
 
162  (53.1) 
90    (29.5) 
53    (17.3) 
 
143   (46.8) 
 
 
63    (20.6) 
12    (3.9) 
 
24    (7.8) 
 
8      (2.6) 
4      (1.31) 






45   (14.7) 
26   (8.5) 






















Table 4:  Treatment modality planned at the first visit in gynecology oncology clinic 
 
 








Surgical treatment n (%) 
 
Cone biopsy 
Total abdominal hysterectomy 
Radical hysterectomy 
 
Non-surgical treatment n (%) 
 
Concurrent chemo-radiation therapy 
Radical radiotherapy 
Palliative radiotherapy 
34  (8.4) 
 
       0 
       2    (0.49) 
       32  (7.9) 
 
369 ( 91.5) 
238   (59.0) 
 60    (14.8) 
      71    (17.6) 
25 (8.1) 
 
      1  (0.32) 
      3  (0.98) 




    175(57.3) 
    43  (14.0) 














Uterine artery embolization 
Stenting and dialysis 
31 (7.6) 
 
        6 
        1 
       14 
        8 
        2 
17 (5.5) 
 
       3 
       0 
       6 
       5 
       3 
 
*In patients planned for radical or palliative radiotherapy  
 
 
Table 5 displays the treatment received by the women. The planned surgical treatment 











Table 5: Treatment received by the cervical cancer patients 
 
 
*HIV negative RH (Stage I=19, Stage IIa1=7)            ** HIV positive RH (Stage 1=7, Stage IIa1=8) 














Surgery cancelled n (%) 
Surgery received n(%) 
6   (17.6) 
28  (6.9) 
6  (24.0) 
19 (6.2) 
 
  0.64 
        Cone biopsy        0      1   (0.32)   
        Total abdominal hysterectomy        2   (0.49)      3   (0.98)   
        Radical hysterectomy (RH) 26 (6.4)*      15 (4.9)**   0.08  
        
        Negative Lymph nodes 21  (80.7)   6   (40.0)   
        Positive Lymph nodes      5   (19.2)   
 
     9   (60.0) 
 
  0.002 
Non-surgical treatment n (%) 341 ( 84.6) 251 (82.2)     0.64 
        
        Concurrent chemo-radiation therapy      179  (44.4)      118 (38.6)  0.002  
        Radical radiotherapy 114  (28.2)     32   (10.4) <0.001 
        Palliative radiotherapy  48    (11.9)     101 (33.1)  <0.001 
       
Supportive care   n(%) 
 
 
34    (8.4) 35  (11.4)   0.007  
***Additional surgical 
procedures n(%) 
21  (5.2) 11 (3.6)  
          Ileal conduit             2            3   
          Colostomy 1 0   
          Nephrostomy 10 2   
          Uterine artery embolization 8 5   
          Stenting and dialysis 0 1   
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The difference in women requiring adjuvant radiotherapy was higher in HIV positive 
group, even when the stage of treatment was breakdown as shown in table 6 below. 
 
 Table 6:       Lymph Node Stage and Radical Hysterectomy 
           HIV negative  n=26          HIV positive  n= 15 
Stages Positive lymph 
nodes n=5 (%) 
Negative lymph 
nodes n=21  
Positive lymph 
nodes n=9 (%) 
Negative lymph 
nodes n=6  
I A1            0           0          0            0 
I A2            0           5          0            0 
I B1   n (%)            3  (25)           9          3 (43)            4 
I B2            0           2          0            0 
II A1 n (%)           2  (28.5)           5          6 (75)            2 
Adjuvant 
treatment n (%) 
          5 (19.2)           0          9 (60)           0 
 
 
Table 7 displays the treatment planned and received by both groups.  Significantly 
more women were changed to supportive care when none was planned (8.4% HIV 










Table 7:  Treatment Planned and Treatment Received by the women with cervical 
cancer 


















Surgery n(%) 34 (8.4) 28 (6.9) 25 (8.1)  19(6.2)   0.55 
       Cone biopsy   0  (0) 0 (0) 1   (0.32) 1(0.32)  
       Total abdominal  hysterectomy   2  (0.49) 2 (0.49) 3   (0.98) 3 (0.98)  
       Radical hysterectomy  32  (7.9) 26(6.4) 21 (6.8) 15(4.9)   0.41 
         
       Negative Lymph nodes  21  6  
       Positive Lymph nodes  
 
5(19.2)  9  (60)   0.002 
Non-surgical treatment n(%) 369 (91.5) 341(84.6) 280 (91.8) 
 
251(82.2)   0.21 
Concurrent chemo-radiation 
therapy  
238 (59.0) 179(44.4) 175 (57.3) 118(38.6)   0.10 
       Radical radiotherapy    60  (14.8) 114(28.2)  43  (14.0) 32  (10.4)   0.001 
       Palliative radiotherapy  71  (17.6) 48 (11.9)  62  (20.3) 101(33.1) <0.001 
         
Supportive care n(%) 
 
0 (0) 34(8.4) 0 (0) 35(11.4) 0.007 
*Additional surgical procedures 
n(%) 
 
        Ileal conduit 
        Colostomy 
        Nephrostomy 
        Uterine artery embolization 


































*Received either Radical or Palliative radiotherapy after the additional surgery 
** Anova test used 
 
 
3.5 Waiting time Period  
Table  8 displays an average waiting period from decision to radical hysterectomy 
(RH), RH performed and RH not performed in HIV negative and HIV positive 
women.  The waiting period (range) given to patients was similar between both 
groups; however, average waiting period  given to patient from decision to planned 









Waiting Time HIV Negative 
n=32 




Average waiting time given from 
decision to surgery  
 
58.38 days 84.92 days <0.05 





n=26 n=15  
RH performed 50 days 72.57 days 
 
0.08 
 n=6 n=6 
 
 





The waiting time to RH performed was the time coincided with the planned date given at 
the time of 1st appointment. In 12 women, six women in either group returned on the 
planned date of surgery which was an average of 93 days and 127 days, respectively, but 
were found to be unsuitable for RH d as the stage had advanced from the initial stage 


























Figure 5 shows the waiting period for RH not performed. It shows the longer waiting 






































Table 9: Average waiting period for radical and palliative radiotherapy in HIV 
negative and positive women 
 







Radical radiotherapy  Mean 
 
                                    ( range) 
88.1 days 
(0-217days) 
83.22days   
(7-210 days) 
0.1 
Palliative radiotherapy Mean 
 
                                     ( range) 
31.07days 
(7- 119 days) 




3.6    Outcome and complication  
Table 10 demonstrates the number of women required change in treatment and its 
causes.  The long waiting period resulted in the change of treatment in different stages 
of cervical cancer. 
 
      Table 10:    Change and causes of change in treatment  
*patient declining treatment, cannot wait for long radical RXT date requesting palliative RXT and 
defaulting follow-up appointment during the treatment phase. 
 















Causes of change in treatment n(%) 
 
         Worsening of performance score 
         Progressive disease(upstaged) 
         Patient related factor 
          Shortage of staff 
 
Recurrent Disease n(%) 
 
         Surgical group 
        Radiotherapy group 
 
 
    27 (28.4) 
    49 (51.5) 
    19 (20.0) 




      3  (20) 
     12 (80) 
 
 
  37   (43.0) 
  32   (37.2) 
  14   (16.2) 




    1 (14.2) 












     Table 11: Complication of surgery and radiotherapy and Deaths 







Surgical complication n (%) 4 (1) 3 (.98) NS 
       
Bleeding 2 1  
            Burst Abdomen 1 1  
            Massive Pulmonary embolism          1 (died) 1  
       
Radiotherapy complication n (%) 15 (3.7) 15 (4.91) NS 
       
           Radiation cystitis 1 2  
           Proctitis 2 3  
           Rectovaginal/vesicovaginal fistula 12 10  
       
Deaths (oncology ward) n (%) 9   (2.2) 10 (3.2) NS 
       




3.7   HIV positive women based on CD4 Count 
The cohort of HIV positive women were further analyzed based on CD4 count (< 
200mm3 and >200mm3) (Table 12 and 13).  Antiretroviral treatment was significantly 
different between the two groups (p <0.001).  In the study population, the average 
CD4 count was 375 mm3.  Furthermore, in women with CD4 count <200mm3, 75 % 
presented in advanced stage in the group not on HAART compared to those On 







Table 12: Clinical characteristics of HIV positive women in CD4 count groups 
 CD4<200mm3 






Age (years) Mean ±SD 
Parity         Median (range) 
*BMI          (kg/mm2) 
 
Hemoglobin n (%) 
               >10 gm/dl 
              8-10 gm/dl 
              <8 gm /dl 
 
Renal failure n (%) 
              GFR <60 
              Dialysis 
 
On  HAART 
NO HAART 
42.43±9.33 




35  (44.3)  
28  (35.4) 
16  (20.2)   
 
 
19   (24.0) 
4     (5.0)   
 
67    (84.8) 






114  (50.4) 
70     (30.9) 
42     (18.5) 
 
 
46     (20.3) 
8       (3.5) 
 
106   (46.9) 















*BMI : Body mass index 
Table 13:  Staging and treatment received in CD4 count sub groups 
      CD4 <200mm3 
            n=79   
         Group A 
      CD4 >200mm3 
           n=226 














0   (0) 4   (5.9) 
3   (25.0) 25  (37.3) 
6   (50.0) 33  (49.2) 








5    (4.1) 7   (6.6) 
41  (34.1) 29  (27.3) 
69   (57.5) 60  (56.6) 
5     (4.1) 10  (9.4) 
 
0.4 








0  (0)              4   (2) 
 
8  (5)             33 (21) 
 
0  (0)             14 (12) 
 
4  (6)             16  (26) 
 
0  (1)              0   (6 ) 
 
 
12  (8)             9  (9) 
 
71 (47)           59 (45) 
 
14  (11)          15 (9) 
 
23  (39)          23 (30) 
 
0    (15)           0  (13) 
P (0.07) 
R(0.32) 
P (R): Planned (Received); CCRT: concurrent chemo-radiation therapy;   RRXT: radical radiotherapy; 




                                                     CHAPTER 4 
                                    DISCUSSION AND LIMITATIONS 
        
       4.1      DISCUSSION  
KwaZulu-Natal is the second most densely populated province of South Africa and 
carries the highest burden of HIV disease (National HIV Prevalence Survey Report 
2008; Antenatal Survey Report, (2010).  Under these circumstances, it is valuable to 
ascertain the cervical cancer burden and to understand how HIV infection influences 
the dynamics of the disease even with HAART coverage.  With this in mind, an audit 
of the clinical profile of HIV positive and HIV negative women with cervical cancer 
in a background of high HIV prevalence was conducted.    
 
This study found a higher HIV sero-prevalence of 39% in women with cervical cancer 
compared to national the HIV Prevalence Survey Report 2008, maximum of 32.9% in  
female (http://www.mrc.ac.za/pressreleases/2009).  This audit also revealed an 
increase in HIV prevalence in women with cervical cancer women compared to 21% 
in 1999 (Moodley 2006) and 21.8% in 2003 (Moodley & Mould, 2005).  Elsewhere in 
Africa, Matovelo et al., (2012) reported an increase of HIV prevalence of 29.7% in 
women with cervical cancer in Tanzania compared to 21% reported by Kahesa et al., 
(2008). This could be due to multiple factors such as early sexual debut, multiple 
partners resulting in women more at risk of acquiring HIV infection as compared to 
men.  
 
HIV infection was found to influence the age of presentation of women with cervical 
cancer in this study.  Our study confirms the earlier studies reported by Lomalisa et 
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al., (2000) and Moodley (2006).  In women under 35 years of age, there was almost 
eight fold increase in HIV positive women presented with cervical cancer.  Abraham 
et al., (2012) reported that HIV positive women were three times more prone to have 
cervical cancer than HIV negative women, and that their risks increased with a low 
CD4 count.  Cai et al., (2010) reported an increase in cervical cancer in younger 
women (< 35 years) over the past 30 years from 2.8% to 15.7%, though the study did 
not consider HIV status.  High HIV prevalence in young women would result in early 
acquisition of HPV infection and its persistence, particularly in women with a low 
CD4 count and high viral load.  HIV positive women have a shorter latency period 
from dysplastic lesions to cervical cancer.  The need for earlier cervical cancer 
screening in South Africa is indicated in the high risk group of HIV positive women 
compared to the Department of Health recommended screening protocol of first Pap 
smear at the age of 30 years. 
 
HIV positive women did not show the high uptake of Pap smear despite the CDC 
guidelines of annual Pap smear.  The poor coverage of Pap smear falls with the health 
care worker/system and women related factors and are missed opportunities by the 
health care workers at hospitals and primary health care facilities about who to screen. 
Poor uptake of cervical screening is multi-factorial.  These include lack of availability 
in deep rural areas, poor quality or shortage of health care providers, poor 
accessibility, and lack of awareness due to education level or poor knowledge of 
disease and its prevention programs.  In addition, women ignore their own wellbeing 
and prioritize their family needs.  Furthermore, capacity to track women with 
abnormal cytology as well as to provide quality assured colposcopy, pathology, and 
treatment services are limited.  Public health spending on the HIV pandemic and 
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tuberculosis remain a major focus of health care budget such that the capacity to 
develop infrastructure for cytology-based cervical cancer screening program remains 
inadequate.  The alternative screening modalities in a low resource setting such as 
Visual Inspection with Acetic acid (VIA) and molecular testing for high-risk types of 
human papillomavirus (HPV) need to be considered in our country.  The data 
regarding VIA value is inconsistent and varies with regions.  The diagnostic values of 
VIA has been reported to be of value in extremely low resource settings where Pap 
smear facility or equipment is not available (Li et al, 2013; Zhang et al 2010).  
However, VIA is not superior to Pap smear in specificity, positive predictive value 
and negative predictive value but has a comparable sensitivity (Albert  et al, 2012). 
The disadvantage of VIA is the necessity of on-going training of the health care 
worker which also need infrastructure. Visual inspection with acetic acid is a poor 
screening test in comparison to HPV testing and cytology in the reduction of incidence 
of cervical cancer and deaths (Sanakaranararyanan et al, 2009). HPV testing was 
found to be superior among the three, viz., VIA and HPV and cytology. 
 
HPV testing has high sensitivity in detecting high grade lesions than cytology (96.1% 
vs. 53.0%) but less specific (90.7% vs. 96.3%) (Cuzick et al, 2006). HPV testing was 
found to be of value in Denny et al, (2010) study. They reported that at the 36 month 
follow-up, in the  screen and treat approach using HPV testing  a 3.6 fold decrease in 
high grade dysplasia was noted as compared to the VIA and treat and no intervention 
group. 
 
In our setting, HPV testing and treat, and HPV testing incorporated into a cervical 
screening program may help to increase the interval of Pap smears in a high risk group 
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if the HPV test is negative. This seems more cost-effective compared to VIA in order 
to decrease the burden of cervical cancer. 
 
There was a significantly higher prevalence of hypertension and diabetes among the 
HIV negative women.  This reflects the older mean age of 55 years in HIV negative 
women compared to the mean age of 41 years in HIV positive women.  However, HIV 
positive women were almost four times at higher risk of having an opportunistic 
infection such as Tuberculosis compared to HIV negative women, which is an 
expected finding in our setting with high HIV prevalence. 
 
In our study, HIV positive women had a higher prevalence of anaemia at their first 
visit compared to HIV negative women.  Advanced stage malignancy, bleeding, poor 
turnover of bone marrow and poor nutritional state are the likely contributory factor to 
anemia (Stuklov NI, 2010). This leads to an increase in the blood transfusion burden 
in our limited resource setting where blood shortage is common.  Anaemic patients 
were referred back to their base hospital for blood transfusion prior to and during the 
treatment period.  Anaemia is probably one of the prognostic factors for advanced 
stage disease and furthermore affects more HIV positive women.  Barkati et al., 
(2013) reported that patients with low hemoglobin usually presented with advanced 
stage disease which contributed to a poor prognosis.   
 
Women with CD4 count of less or more than 200 mm3 did not seem to influence the 
clinical characteristics in our study.  However, correlation of timing of HAART 
initiation and cervical cancer diagnosis was not established, as this information was 
not recorded in patient’s records.  There were only a few women with CD4 count 
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<200mm3 who were referred for HAART, and this group had an advanced staged 
disease.  As cervical cancer is an AIDS-defining disease, all HIV positive women with 
cervical cancer should have been referred for HAART, however but no comment was 
found in the patient records. 
       
HIV infection did not influence the stage presentation and histology of cervical cancer 
in the study. HIV positive women is more at risk of persistence of HPV infection, high 
grade cervical dysplasia compared to HIV negative (Peedicayil et al, 2009).            
Kinney et al, (2003), reported the detection of early stage cervical cancer by cytological 
screening. Yamada et al, (2008) reported the higher detection of high -grade squamous 
intraepithelial lesions and cancer on cytology in HIV positive women compared to HIV 
negative women.  HIV positive women should have an annual Pap smear as a part of 
their health care package.  In a background of high HIV prevalence, a higher incidence 
of early stage cervical cancer presentation may be expected due to detecting  
premalignant or early malignant changes (micro invasive disease) earlier by Pap smear 
or by clinical evaluation of the symptomatic women; however, our study did not find 
any difference.  Of concern in this study was that nearly 8% of women presented with 
stage IV cervical cancer.  Advanced staged disease presentation highlights the poor 
cervical cancer screening uptake in the community, thereby increasing the burden of 
disease and decreasing the survival of women.  A study done in Harare reported that 
80% of women presented with advanced disease (stage IIb and above) (Chirenje et al, 
2000).  In this study, about 92 % women presented in advanced stage cervical cancer 
requiring radiotherapy treatment.  Reasons for delayed presentation to tertiary centers 
are multifactorial, and include health care system and patient related factors.  In the 
health care system, there was a long waiting period to the first visit to gynecology 
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oncology clinic while some patient required a second visit before deciding on definitive 
treatment due to incomplete workup information, and/or inappropriate referral.  In some 
instances, the histology result was not to be found or not sent resulting in repeat biopsy.  
Poor socio-economic factors and low level of education contributed to delays in seeking 
health advice and missing their scheduled appointment, resulting in advanced stage 
presentation. 
 
Advanced staged disease may result in renal failure and dialysis adds to the cost of 
care in women suitable for radical radiotherapy.  Furthermore, due to poor social 
support services including hospice services, women requiring palliative care consume 
lot of health resources in our district hospitals.   In our study, 22.9% of women did not 
return on their appointed date of treatment.  All these women had advanced disease 
and poor health status and demised before their appointed date.  Greater socio-political 
will is required to change the face of advanced cervical cancer in our country. 
 
The long waiting period in the management of any malignancy does influence the 
disease progression and survival outcome.  In Durban, only two centers (IALCH and 
ADH) provide chemotherapy and radiotherapy, with IALCH being the only center for 
brachytherapy.  The waiting time for women requiring radical radiotherapy was about 
3 month and those having palliative radiotherapy were just under 1 month. The 
reasons for the long waiting time included shortage of radiotherapist in the province, 
and few radiotherapy machines.  These radiotherapy machines were old and 
experienced breakdowns which took long to repair and replace in 2010.  In addition, 
there was an industrial strike action in 2009 and 2010 that also contributed to long 




The time period from diagnosis to treatment is important regarding survival outcome 
of women with cervical cancer.  Dahrouge et al., (2005) reported that a longer waiting 
period of more than 6-8 weeks would affect the survival of women in radical 
radiotherapy treatment.  Our study showed that long waiting times affected the 
surgical and non-surgical planned treatment in women with cervical cancer.  The long 
waiting period allowed the health status to deteriorate and progression of disease, 
which resulted change of planned treatment in certain proportion of women. 
Furthermore, long waiting periods to treatment also created anxiety in women and 
families, contributing to 18% cause of changes in treatment.   This information was 
recorded from the patient’s notes. The long waiting period resulted the change in 
planned treatment of women with cervical cancer. The causes of change in treatment 
include worsening of their performance score and progressive disease such as 
developing renal failure or higher stage when these women presented on their date of 
treatment. In addition, patient related factors also contributed to the change in planned 
treatment. There were few (7) women with cervical cancer who were counselled about 
the radical radiotherapy and explained about the reasons for long waiting list for 
treatment due to the shortage of radiographer and oncology staff.  This group of 
patients had an advanced stage (IIIB) and the waiting period was between 5-7 months 
for radical radiotherapy. These patients declined to wait that long and therefore 
palliative radiotherapy was offered which had a shorter waiting period of 3-4 weeks. 
Other patient related factors were missing their appointment during radical 
radiotherapy treatment and subsequently presented in poor clinical condition resulted 




The reason for long waiting period for radical hysterectomy in HIV positive women 
was not mentioned in the patient’s record.  This is one of the limitations of a 
retrospective study, as the health care worker did not record the reason for the delays, 
but presumably may have been low CD4 count, time needed  to respond to HAART or 
presence of active Tuberculosis.  Other contributory factors could include physician 
absence in industrial action, vacation and leave from duty. These factors would result in 
the same waiting time for both groups.  The long waiting period resulted in disease 
progression and also contributed to the need for adjuvant therapy due to positive 
lymph nodes, significantly more in HIV positive women.  HIV positive women with 
cervical cancer need to be prioritized on the treatment list in order to decrease the 
progression of disease and improve the survival. As initially stated one case a month, 
therefore it seems there is no acceptable explanation for this delay.  
 
In our study, women were compliant with their appointment date however the delays 
in treatment contributed to the change in planned treatment highlighting health system 
related factors.  This study highlights that a prolonged waiting time adversely affected 
the planned treatment in especially HIV positive women with cervical cancer.  The  
deficiency in the health care system include shortage of staff, late referral and delay in 
initiating the definitive treatment in women with cervical cancer further  increases the 
advanced staged disease burden and eventually less women get radical treatment. 
Moreover, there is no cancer registry follow-up system to assess recurrent disease or 
complications in the radiotherapy group.   Early referral and short waiting time to 






This was a retrospective study which had limitation regarding the availability of some 
data such as viral load, HAART initiation in cervical cancer women, and reasons for 
long waiting time for surgery in HIV positive women. 
A proportion of women who were diagnosed with cervical cancer may have died in 
their base hospital or at home before they reached tertiary level care.  HIV related 





















                                                           CHAPTER 5 
                                  CONCLUSION AND RECOMMENDATIONS 
 
     5.1 CONCLUSION 
HIV prevalence was 39% among women presenting with cervical cancer, a disease 
that is increasing in South Africa.  The HIV positive women presenting with cervical 
cancer did not influence the stage of presentation, but presented at an earlier age than 
the HIV negative women and were more at risk of developing anaemia.  Ninety two 
percent of women presented in advanced staged disease and required radical or 
palliative radiotherapy.  The long waiting period had significantly affected the HIV 
positive women with cervical cancer in the surgical group and in the radiotherapy 
treatment group compared to HIV negative women. 
 
Our study highlighted the need for more radiotherapy services due to advanced stage 
cancer of cervical cervix at presentation.  This could decrease the prolonged waiting 
period to treatment in these women and thereby improve their 5 year survival 
outcome.   
 
5.2 RECOMMENDATIONS 
The following recommendations are made following this study:  
 Establishment of a Cancer registry in South Africa is needed to reflect the 
magnitude of the cervical cancer burden.  It should have a record of the patient 
and periodic follow up Pap smear after treatment to indicate the survival 
outcome of treatment given, magnitude of recurrent disease burden, and 
monitor the survival of these women.  In addition, it should keep a record of 
50 
 
complications of treatment, psychosexual morbidity and follow up 
management of complications and outcome.  This would guide our 
management strategies by enabling periodic audits. 
 
 Pap smear programs for HIV negative and HIV positive women needs to be 
utilized effectively at every facility to detect cervical dysplasia earlier and refer 
if indicated.  Professional nursing sisters can deliver information about the Pap 
smear importance, sexually transmitted disease including HIV infection testing 
to women in gynecology clinics or family planning clinics in each facility 
similar to mother and child health education in antenatal clinics.  In addition, 
opportunity to educate women about Pap smear who attend antenatal clinics 
can also be utilized. 
 
Women empowerment is an essential component to improve their health.  
Health care workers both at hospital and primary health centers must utilize 
every opportunity to educate women about cervical cancer prevention program 
and HIV testing.  Health facilities need to improve the uptake by adherence to 
the national cervical cancer screening program and the wellness clinic protocol 
of annual Pap smears in HIV positive women.  Furthermore, community 
education and acceptability about the prevention programs need to be 
improved and can be assisted by the media, primary health care workers and 
by the social and religious scholars in the region.  
Survey questionnaires to assess the knowledge of Pap smears and establish 
utilization of the service among the women attending gynecology clinics need 




The implementation of an effective cervical cancer screening program requires 
sophisticated health infrastructure which is limited in developing countries. 
There may be probably the need to consider low cost effective strategies for 
cervical cancer screening such as Visual Inspection with Acetic Acid and 
Screen and Treat approach.   
 
 Women with cervical cancer need to be referred and treated earlier to improve 
the outcome.  The health services need to be improved in outreach health 
facilities and offer periodic in-service refresher courses or training to health 
care workers and nurses to update their knowledge. Feedback of the magnitude 
of the disease and outcome may assist them to improve the Pap smear service, 
prioritize these women with cervical cancer and refer them earlier.  
 
 Continuity of care by the same medical personnel is important in terms of 
management and outcome which is less practiced in peripheral hospitals due to 
change over of junior doctors.  
 
 Oncology services need to be increased and staff members recruited to address 
the long waiting period and prioritize the early stage disease for surgery to 







Recommendations for our department. 
In our department oncology services need to be improved in the following 
sectors. 
 More gynaecology-oncology clinics to increase the patient number. 
 Increase the number of oncology trained nurses and radiographers to 
provide chemotherapy and radiotherapy. 
 More and new radiotherapy machines are required in the department to 
serve the major bulk of the advanced stage disease. 
 More gynaecology -oncology operating slates to reduce the waiting time 
for women for their oncology surgery. 
 
After implications of the above changes have been made a repeat audit should 
be performed to see any improvement in the services and outcome of 
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                                                          APPENDIX A 
DATA SHEET 
 
Year                                                                                   Study No   
KZ no.                                   Age                   Parity                       
Height                Weight                     BMI                                
Race (African=1, Indian=2, white=3, coloured =4)     
Medical History:   (Hypertension = 1, Diabetes = 2, others=3)  
 Opportunistic infections (OI) (No=1, Yes=2)  
HIV Status:    (Negative=1, Positive=2, unknown =3)                         
CD4 count (<200=1, 200-350=2, >350=3, unknown =4) 
HAART (No=1, Yes=2, ref for ARVS=3)     
Histology Type: (Squamous cell ca =1, Adenosq. ca= 2, adenoca=3, undiff ca=4, small 
cell ca=5, others=6) 
Grade   (Well diff=1, Moderate diff=2, poorly differ=3) 
Previous Pap smear (N=1, Y=2, not done =3)                 Pap smear not documented   
Prev.Colposcopy (N=1, Y=2, NA=3, Normal=4)                  
 Abnormality (CIN=1, HPV infection=2, ca=3, others = 4) 
Clinical staging of cervical cancer at IALCH (1-4)         
 Extent (a=1, b=2, a1=3, a2=4, b1=5, b2=6)   
Investigations: 
Hb               urea                     Creatinine                CXR 20 (N=1, Y=2)  
Hydronephrosis (N=1, Y=2)            Liver (N=1, Y=2)              Bladder (N=1, Y=2) 
Rectum (N=1, Y=2)                  Co-incidental findings/others: No=1,yes=2,others=3) 
GFR  (<60=1, > 60=2) 
Zubrod score (1-4)  
RX planned  at 1st visit: Rx (sx=1, CCRT=2, RRXT=3, PRXT=4, SC=5,others=6) 
Date of RX decision=               Date of RX to be given=                           
Time interval between = 
Did the patient return on specified date (N=1, Y=2,) 
Was the stage of the disease same (N=1, Y=2)                             
If No, final stage at f-up visit (1-4): 






































Any change in Rx (N=1, Y=2)                          
If Yes, reason (Z score=1, stage=2, shortage of staff=3, patient related factors =4, 
others=5) 
 
SX received:   (CB =1, TAH=2, RH=3, T=4, IC=5, Colos=6, neph=7, other=8) 
Stage I (CB =1, TAH=2, RH =3, CCRT=4)                  
W/Sx (Neg.L.Nodes=1, Pos.L.Nodes=2, nodes not done=3)  
W/SX(CCRT=1,No RXT=2, RT=3, No treatment=4)                    
StageII (SX=1, Adj.RXT=2,No RXT=3,others=4) 
 
Sx complication:   (Bleeding=1, VTE=2, Anaesthetic =3, wound infection=4, Burst 
abdomen =5, others = 6)   
RXT complication: (Rad. Cystitis=1, Proctitis=2, Colitis=3, VVF and RVF =4)                      
Recurrent disease (Y=1)                   Mortality (Alive=1, Died =2) 
Follow-up plan (Lost/Fup=1, BH/Fup=2, U/Fup=3, No record=4) 
 
 
(Sx=surgery, CCRT =Concurrent chemo-radiation therapy, PRXT=Palliative 
radiotherapy, RRXT=radical radiotherapy, PCTX=Palliative chemotherapy, 
SC=Supportive Care) 
(CB =Cone Biopsy, TAH=Total abdominal hysterectomy, RH=Radical Hysterectomy, 
T=Trachelectomy, IC=Ileal Conduit, Colos=colostomy, neph=nepherostomy, other=8) 
(VVF and RVF =Vesicovaginal fistula and Rectovaginal fistula) 























                                                    APPENDIX B 
       Revised FIGO staging of cervical cancer  
Stage I - Limited to the cervix, divided into Ia & Ib 
Ia- Diagnosed only by microscopy; no visible lesions 
Ia1 - Stromal invasion less than 3 mm in depth and 7 mm or less in  horizontal                
spread 
Ia2 - Stromal invasion between 3 and 5 mm in depth with horizontal spread of 7 mm 
or less 
Ib - Visible lesion or a microscopic lesion with more than 5 mm of depth or 
horizontal   spread of more than 7 mm 
Ib1 - Visible lesion 4 cm or less in greatest dimension 
 Ib2 - Visible lesion more than 4 cm 
Stage II - invades beyond cervix (new) 
IIa - Without parametrial invasion, but involve upper 2/3 of vagina 
IIa1-Involvement of the upper two-thirds of the vagina, without parametrial 
invasion, Lesions less or equal to 4 cm in greatest dimension 
IIa 2- Lesion more or equal to 4 cm in greatest dimension without parametrial 
involvement 
IIb - With parametrial invasion 
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Stage III - Extends to pelvic wall or lower third of the vagina 
IIIa - Involves lower third of vagina with no extension to pelvic side walls 
IIIb - Extends to pelvic wall and/or causes hydro-nephrosis or non-functioning 
kidney 
Stage IV -   Involve the regional organs & distant metastasis  
IVa- Invades mucosa of bladder or rectum  
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